admin
Americans are waking up to a new economic story driven not by the halls of Congress but by a class of drugs known as GLP-1s — think Ozempic, Wegovy and Mounjaro — that analysts say could meaningfully shift GDP and productivity in the years ahead. Goldman Sachs and other economists have suggested widespread adoption could lift U.S. GDP by as much as around one percent as obesity-related disease costs fall and workers become healthier and more productive.
But before anyone starts celebrating, taxpayers and private employers are already feeling the sticker shock of these miracle drugs. U.S. spending on GLP-1s exploded in recent years — into the tens of billions — with reports showing dramatic increases in prescriptions and enormous price tags that leave families and insurers on the hook.
That surge in cost is showing up in company balance sheets and public plans alike, with Medicare and major insurers facing eye-popping budget impacts if coverage expands without restraint. Analysts and reporters warn Medicare spending would climb by tens of billions over a decade under broad coverage scenarios, and several health plans and employers have reported disruptions and losses tied to rising GLP-1 claims. Conservatives should be alarmed that a private-sector breakthrough is morphing into another giant entitlement-style bill unless policymakers act.
There’s no doubt these drugs can improve health and reduce certain obesity-related costs — that’s part of why markets and investors are so excited — but the benefits won’t automatically translate to a free lunch for taxpayers. Think tanks and economic modelers estimate productivity gains and healthcare savings, yet those figures are paired with complex second-order effects and enormous upfront spending, meaning private payers, not Washington, should be the first line of cost containment.
We’re also seeing industry-level disruption that politicians and bureaucrats rarely discuss: restaurants, food suppliers, and other consumer-facing sectors could lose revenue as millions change diets and lifestyles, while fashion and wellness industries pivot to meet new demand. Supply-chain analyses show potential ripple effects across dozens of industries if consumption patterns shift, highlighting that economic “winners” from GLP-1s will be offset by real losers — mostly small businesses and workers who can’t adjust overnight.
Instead of reflexively expanding public coverage and letting Big Pharma set the national agenda, conservatives should press for market-based solutions: transparent pricing, expanded access to generics and biosimilars, smarter employer-driven benefit design, and incentives for competition that actually lower costs. Surveys show many large employers are hesitant or conditional about covering these medications for weight loss, which proves private negotiation and plan design can be effective levers if used wisely.
This moment is a test of prudence: we can cheer a medical breakthrough while refusing to mortgage the country for Pharma’s profits or drown paychecks under rising premiums. Hardworking Americans deserve innovation that lowers suffering and saves money, not another entrenched entitlement that transfers risk from consumers to government. Lawmakers and executives should remember that protecting families and fiscal sanity means putting markets and accountability first.
